“The 630,871 increase in research and development expenses in the quarter ended January 31, 2019 versus the comparative previous fiscal quarter is primarily due Antigen’s increase of expenses.”
Good $NGIO.
(1)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
